DE69630423D1 - Immunoglobuline die durch Mischung mit einem Komponenten von Histamin aktiviert wurden - Google Patents

Immunoglobuline die durch Mischung mit einem Komponenten von Histamin aktiviert wurden

Info

Publication number
DE69630423D1
DE69630423D1 DE69630423T DE69630423T DE69630423D1 DE 69630423 D1 DE69630423 D1 DE 69630423D1 DE 69630423 T DE69630423 T DE 69630423T DE 69630423 T DE69630423 T DE 69630423T DE 69630423 D1 DE69630423 D1 DE 69630423D1
Authority
DE
Germany
Prior art keywords
activated
immunoglobulin
agent
histamine
immunoglobulins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69630423T
Other languages
English (en)
Other versions
DE69630423T2 (de
Inventor
Haruo Yoshii
Mitsuru Naiki
Yuriko Fukata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Zoki Pharmaceutical Co Ltd
Original Assignee
Nippon Zoki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co Ltd filed Critical Nippon Zoki Pharmaceutical Co Ltd
Publication of DE69630423D1 publication Critical patent/DE69630423D1/de
Application granted granted Critical
Publication of DE69630423T2 publication Critical patent/DE69630423T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
DE69630423T 1995-08-11 1996-08-08 Immunoglobuline die durch Mischung mit einem Komponenten von Histamin aktiviert wurden Expired - Fee Related DE69630423T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7227045A JPH0959180A (ja) 1995-08-11 1995-08-11 活性化免疫グロブリン
JP22704595 1995-08-11

Publications (2)

Publication Number Publication Date
DE69630423D1 true DE69630423D1 (de) 2003-11-27
DE69630423T2 DE69630423T2 (de) 2004-06-17

Family

ID=16854669

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69630423T Expired - Fee Related DE69630423T2 (de) 1995-08-11 1996-08-08 Immunoglobuline die durch Mischung mit einem Komponenten von Histamin aktiviert wurden

Country Status (10)

Country Link
US (1) US6627194B1 (de)
EP (1) EP0758656B1 (de)
JP (1) JPH0959180A (de)
KR (1) KR100436811B1 (de)
CN (1) CN1108818C (de)
AT (1) ATE252603T1 (de)
AU (1) AU713296B2 (de)
CA (1) CA2183020A1 (de)
DE (1) DE69630423T2 (de)
TW (1) TW442495B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10212246A (ja) * 1997-01-30 1998-08-11 Nippon Zoki Pharmaceut Co Ltd 経口投与用製剤
TW541179B (en) * 1997-03-19 2003-07-11 Green Cross Corp Process for preparing immunoglobulin preparation
JP2000143536A (ja) 1998-11-13 2000-05-23 Nippon Zoki Pharmaceut Co Ltd 抗浮腫剤
DE19944122A1 (de) * 1999-09-15 2001-03-29 Wolfgang Loh Histamin-Immunglobulin-Komplexe zur Behandlung von entzündlichen Erkrankungen bei Säugetieren
KR20070108320A (ko) * 2006-03-20 2007-11-09 전숙영 알레르기질환 및 자가면역질환의 치료를 위한 약학적조성물, 그의 용도 및 알레르기질환 및 자가면역질환의치료방법
RU2502521C2 (ru) * 2010-08-06 2013-12-27 Олег Ильич Эпштейн Комплексное лекарственное средство для лечения бактериальных инфекций и способ лечения бактериальных инфекций
RU2505312C2 (ru) * 2010-08-06 2014-01-27 Олег Ильич Эпштейн Комплексное лекарственное средство для лечения гриппа различных типов
CN110801013B (zh) * 2019-11-19 2023-03-31 西北农林科技大学 一种生物化学法制备非过敏生漆或漆酚的方法及其产品

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873697A (en) 1972-11-11 1975-03-25 Mack Chem Pharm Histamine antigen
RO72676A2 (ro) * 1977-07-15 1982-08-17 Institutul "Dr.Ioan Cantacuzino",Ro Procedeu de determinare a continutului in anticorpi speci†ici antiamine biologic active a gamaglobulinelor
JPS5585526A (en) * 1978-12-23 1980-06-27 Nippon Zoki Pharmaceut Co Ltd Remedy for allergic disease
US4704273A (en) 1982-05-17 1987-11-03 Mcmichael John Methods and materials for treatment of rheumatoid arthritis
US4705685A (en) * 1982-05-17 1987-11-10 Mcmichael John Methods and materials for treatment of disease states involving immunological factors
JPS58225027A (ja) * 1982-06-23 1983-12-27 Fujirebio Inc ヒスタミン加グロブリン製剤
US4705687A (en) 1985-06-17 1987-11-10 Ortho Pharmaceutical (Canada) Ltd. Treatment of autoimmune diseases such as rheumatoid arthritis with suppressor factor
US5112738A (en) 1985-07-03 1992-05-12 Miles Inc. Histamine derivatives, immunogen conjugates and antibodies raised thereto
US5244902A (en) 1989-08-21 1993-09-14 Beth Israel Hospital Association Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
IT1237475B (it) 1989-10-06 1993-06-07 Allergeni modificati chimicamente e procedimento per la loro preparazione
US5192773A (en) 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
JP3193205B2 (ja) * 1993-08-09 2001-07-30 日本臓器製薬株式会社 好酸球増多抑制剤

Also Published As

Publication number Publication date
KR970009812A (ko) 1997-03-27
EP0758656B1 (de) 2003-10-22
EP0758656A2 (de) 1997-02-19
ATE252603T1 (de) 2003-11-15
JPH0959180A (ja) 1997-03-04
US6627194B1 (en) 2003-09-30
KR100436811B1 (ko) 2004-08-25
TW442495B (en) 2001-06-23
AU713296B2 (en) 1999-11-25
DE69630423T2 (de) 2004-06-17
EP0758656A3 (de) 1997-08-06
AU6203396A (en) 1997-02-13
CN1148505A (zh) 1997-04-30
CN1108818C (zh) 2003-05-21
CA2183020A1 (en) 1997-02-12

Similar Documents

Publication Publication Date Title
ATE235917T1 (de) Verwendung von anti-tnf-antiköpern als arzneimittel zur behandlung von erkrankungen mit einem erhöhten interleukin-6 serumspiegel
NZ316710A (en) Il-8 receptor antagonists and method of treating chemokine mediated diseases
DE69735763D1 (de) Intravaskuläre verabreichung von medikamenten durch elektroporation
PT76052B (de) Neue derivate bicyclischer aminosaeuren verfahren zu ihrer herstellung diese enthaltende mittel und deren verwendung sowie neue bicyclische aminosaeuren als zwischenstufen und verfahren zu deren herstellung
DE69603240D1 (de) Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
PT76424A (de) Neue derivate bicyclischer aminosaeuren verfahren zu ihrer herstellung diese enthaltende mittel und deren verwendung sowie neue bicyclische aminosaeuren als zwischenstufen und verfahren zu deren herstellung
PT84427A (de) Hybridinterferone deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
DE69325920T2 (de) Schmiermittelherstellung durch isomerisierung von lösungsmittelextrahierten einsatzstoffen
AU4089889A (en) Method of treating skin injuries using thromboxane a2 receptor antagonists
SE9502893D0 (sv) Användning av kollagenas
DE69630423D1 (de) Immunoglobuline die durch Mischung mit einem Komponenten von Histamin aktiviert wurden
DE69325393T2 (de) Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen
DE3486453D1 (de) Monoklonale Antikörper gegen neue Faktor-VIII Gerinnungspolypeptide
DE69129930T2 (de) Verfahren zur Herstellung der Elektrodenmetallisierung von einem Transistor
DE3581288D1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
ATE58172T1 (de) Monoklonale antikoerper gegen alpha-2 interferon und hybridomas, die solche antikoerper produzieren.
ATE40369T1 (de) Purinderivate.
ATE210645T1 (de) Pyridiniumderivate und ihre verwendung zur bestimmung von bindegewebeerkrankungen bei menschen und tieren
ATE25195T1 (de) Verwendung von d,l- und d-carazolol zur herstellung von antiglaukommitteln sowie arzneimittel, die d-carazolol enthalten.
EP1416282A3 (de) Verfahren zur Identifizierung von Zusammensetzungen verwendbar in der Therapie von Knochenkrankheiten
PT81529B (de) Neue substituierte phenylpiperazinderivate verfahren zu deren herstellung und die verwendung substituierter phenylpiperazinderivate als aggressionshemmer fuer tiere
ATA133183A (de) Verfahren zur herstellung von neuen substituierten thiamorpholinonderivaten und deren sulfoxiden
ATE141614T1 (de) Neue peptidderivate im prozess von zelladhäsion wirksam, verfahren zur deren herstellung und pharmazeutische zusammensetzungen die sie enthalten
ATE47838T1 (de) Derivate bicyclischer aminosaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue bicyclische aminosaeuren als zwischenstufen und verfahren zu deren herstellung.
EP0264790A3 (de) Neue Hefeexpressionsvektoren für IFN-omega, Verfahren zu ihrer Herstellung und deren Verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee